| 1 |
33897064 | Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. | 2021 Jan 12 |
1 |
| 2 |
34117140 | Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder. | 2021 Jun 3 |
8 |
| 3 |
34605737 | Role of amino acids at positions 34, 296, and 486 of cytochrome P450 2D6 in the stimulatory and inhibitory effects of psychotropic agents on dopamine formation from p-tyramine. | 2021 Nov |
1 |
| 4 |
29988737 | Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. | 2018 |
5 |
| 5 |
28361099 | A de novo splice site mutation in EHMT1 resulting in Kleefstra syndrome with pharmacogenomics screening and behavior therapy for regressive behaviors. | 2017 Mar |
1 |
| 6 |
21739267 | The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. | 2012 Jan |
6 |
| 7 |
20547595 | CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. | 2011 Jul |
6 |
| 8 |
21277363 | Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes. | 2011 Apr 10 |
1 |
| 9 |
20118554 | Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients. | 2010 |
2 |
| 10 |
18609433 | A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder. | 2009 |
1 |
| 11 |
19225771 | Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. | 2009 Jul |
3 |
| 12 |
18691982 | Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. | 2008 Jul |
1 |
| 13 |
18978520 | Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration. | 2008 Dec |
4 |
| 14 |
17484519 | Identification of human cytochrome P450 enzymes involved in the major metabolic pathway of fluvoxamine. | 2007 Feb |
2 |
| 15 |
17516189 | Prolonged anticholinergic delirium following antihistamine overdose. | 2007 Jun |
1 |
| 16 |
16205777 | Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. | 2006 Apr |
6 |
| 17 |
16226034 | Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. | 2005 Dec |
2 |
| 18 |
15199661 | Some aspects of genetic polymorphism in the biotransformation of antidepressants. | 2004 Jan-Feb |
1 |
| 19 |
12610741 | CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects. | 2003 Feb |
1 |
| 20 |
12618595 | Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. | 2003 Mar |
1 |
| 21 |
12883230 | Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. | 2003 Aug |
1 |
| 22 |
14703714 | Metabolic drug interactions with new psychotropic agents. | 2003 Oct |
1 |
| 23 |
11876575 | Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. | 2002 Feb |
1 |
| 24 |
11907488 | Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). | 2002 Mar |
1 |
| 25 |
11519155 | [Pharmacokinetics and drug interactions of antidepressive agents]. | 2001 Aug |
1 |
| 26 |
11791895 | The major fluvoxamine metabolite in urine is formed by CYP2D6. | 2001 Nov |
5 |
| 27 |
10774624 | Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? | 2000 Apr |
1 |
| 28 |
10917404 | Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes. | 2000 Aug |
1 |
| 29 |
10954064 | Low dosage of levomepromazine did not increase plasma concentrations of fluvoxamine. | 2000 Jul |
2 |
| 30 |
11085201 | Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. | 2000 Oct |
1 |
| 31 |
10051063 | Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. | 1999 Feb |
1 |
| 32 |
10211917 | CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. | 1999 Apr |
1 |
| 33 |
10471171 | Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors. | 1999 May |
1 |
| 34 |
9617978 | Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. | 1998 Jun |
6 |
| 35 |
9757149 | Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. | 1998 Sep |
4 |
| 36 |
9817620 | Differences in interactions of SSRIs. | 1998 Sep |
1 |
| 37 |
9174682 | Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. | 1997 |
3 |
| 38 |
9184622 | Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. | 1997 |
1 |
| 39 |
10950475 | Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. | 1997 Apr |
1 |
| 40 |
8823236 | Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. | 1996 Aug |
3 |
| 41 |
8838442 | Venlafaxine oxidation in vitro is catalysed by CYP2D6. | 1996 Feb |
1 |
| 42 |
8880055 | Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. | 1996 |
3 |
| 43 |
8885123 | Bupropion plasma levels and CYP2D6 phenotype. | 1996 Oct |
2 |
| 44 |
8968657 | Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. | 1996 Dec |
2 |
| 45 |
8986013 | Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. | 1996 Dec |
1 |
| 46 |
7622807 | Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. | 1995 Mar |
1 |
| 47 |
8567194 | Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. | 1995 |
1 |
| 48 |
8587855 | Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. | 1995 Nov-Dec |
1 |
| 49 |
8685072 | Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. | 1995 Jun |
1 |
| 50 |
8846617 | Overview of the pharmacokinetics of fluvoxamine. | 1995 |
2 |